While VYNE Therapeutics surpassed EPS estimates, indicating operational efficiency and cost management, the miss on sales forecasts could concern investors about revenue growth. The significant year-over-year improvement in both EPS and sales, however, suggests a positive trajectory. The mixed results may lead to a neutral short-term impact on the stock price as investors weigh the positives against the concerns.